Division of Nephrology, University of Washington School of Medicine, Seattle WA; Kidney Research Institute, University of Washington School of Medicine, Seattle WA; Institute for Stem Cell and Regenerative Medicine, University of Washington School of Medicine, Seattle WA; Department of Medicine, University of Washington School of Medicine, Seattle WA.
Division of Nephrology, University of Washington School of Medicine, Seattle WA; Kidney Research Institute, University of Washington School of Medicine, Seattle WA; Institute for Stem Cell and Regenerative Medicine, University of Washington School of Medicine, Seattle WA; Department of Medicine, University of Washington School of Medicine, Seattle WA.
Am J Kidney Dis. 2018 Jun;71(6):874-883. doi: 10.1053/j.ajkd.2018.02.347. Epub 2018 Mar 30.
CRISPR is a nuclease guidance system that enables rapid and efficient gene editing of specific DNA sequences within genomes. We review applications of CRISPR for the study and treatment of kidney disease. CRISPR enables functional experiments in cell lines and model organisms to validate candidate genes arising from genetic studies. CRISPR has furthermore been used to establish the first models of genetic disease in human kidney organoids derived from pluripotent stem cells. These gene-edited organoids are providing new insight into the cellular mechanisms of polycystic kidney disease and nephrotic syndrome. CRISPR-engineered cell therapies are currently in clinical trials for cancers and immunologic syndromes, an approach that may be applicable to inflammatory conditions such as lupus nephritis. Use of CRISPR in large domestic species such as pigs raises the possibility of farming kidneys for transplantation to alleviate the shortage of donor organs. However, significant challenges remain, including how to effectively deliver CRISPR to kidneys and how to control gene editing events within the genome. Thorough testing of CRISPR in preclinical models will be critical to the safe and efficacious translation of this powerful young technology into therapies.
CRISPR 是一种核酸酶制导系统,能够在基因组内快速有效地编辑特定的 DNA 序列。我们回顾了 CRISPR 在肾脏疾病的研究和治疗中的应用。CRISPR 能够在细胞系和模式生物中进行功能实验,验证来自遗传研究的候选基因。此外,CRISPR 已被用于建立源自多能干细胞的人类肾脏类器官中遗传疾病的第一个模型。这些基因编辑类器官为多囊肾病和肾病综合征的细胞机制提供了新的见解。基于 CRISPR 的细胞疗法目前正在癌症和免疫综合征的临床试验中进行,这种方法可能适用于狼疮性肾炎等炎症性疾病。在猪等大型家畜中的应用提出了为移植而养殖肾脏以缓解供体器官短缺的可能性。然而,仍存在重大挑战,包括如何有效地将 CRISPR 递送到肾脏以及如何控制基因组内的基因编辑事件。在临床前模型中对 CRISPR 进行彻底测试对于将这项强大的新技术安全有效地转化为治疗方法至关重要。